OBJECTIVES: Screening method of endometrial cancer (EC) has not been established yet. Our study was to explore serum biomarkers of EC patients using surface-enhanced laser desorption and ionization-time-of-flight mass spectrometry (SELDI-TOF MS). METHODS: Serum samples from 65 EC patients and 40 controls were analyzed by SELDI-TOF MS (training set). Single- and multi-variant analyses were performed to compare protein profiles in serum of EC patients and healthy controls. Subsequently, blind test set including 40 EC patients and 40 controls were analyzed for validation. RESULTS: A panel of four biomarker candidates were selected in training set analysis. These markers could also distinguish stage I patients from controls. Among them, two biomarkers were purified and identified as apolipoprotein A1 and a modified form of apolipoprotein C1. Screening for blind test set using dual-biomarker analysis yielded a sensitivity of 82% and a specificity of 86%. CONCLUSIONS: Involvement of apolipoproteins with EC is first suggested in this study. In addition to possibility of screening method for EC, findings of these new biomarkers might be related with carcinogenesis or predisposition to EC.
OBJECTIVES: Screening method of endometrial cancer (EC) has not been established yet. Our study was to explore serum biomarkers of EC patients using surface-enhanced laser desorption and ionization-time-of-flight mass spectrometry (SELDI-TOF MS). METHODS: Serum samples from 65 EC patients and 40 controls were analyzed by SELDI-TOF MS (training set). Single- and multi-variant analyses were performed to compare protein profiles in serum of EC patients and healthy controls. Subsequently, blind test set including 40 EC patients and 40 controls were analyzed for validation. RESULTS: A panel of four biomarker candidates were selected in training set analysis. These markers could also distinguish stage I patients from controls. Among them, two biomarkers were purified and identified as apolipoprotein A1 and a modified form of apolipoprotein C1. Screening for blind test set using dual-biomarker analysis yielded a sensitivity of 82% and a specificity of 86%. CONCLUSIONS: Involvement of apolipoproteins with EC is first suggested in this study. In addition to possibility of screening method for EC, findings of these new biomarkers might be related with carcinogenesis or predisposition to EC.
Authors: I K Kolasa; A Rembiszewska; A Janiec-Jankowska; A Dansonka-Mieszkowska; A M Lewandowska; B Konopka; J Kupryjańczyk Journal: Gynecol Oncol Date: 2006-06-21 Impact factor: 5.482
Authors: Y Kanamori; J Kigawa; H Itamochi; M Shimada; M Takahashi; S Kamazawa; S Sato; R Akeshima; N Terakawa Journal: Clin Cancer Res Date: 2001-04 Impact factor: 12.531
Authors: G L Mutter; M C Lin; J T Fitzgerald; J B Kum; J P Baak; J A Lees; L P Weng; C Eng Journal: J Natl Cancer Inst Date: 2000-06-07 Impact factor: 13.506
Authors: Helga B Salvesen; Ingunn Stefansson; Ellen I Kretzschmar; Paula Gruber; Nicola D MacDonald; Andy Ryan; Ian J Jacobs; Lars A Akslen; Soma Das Journal: Int J Oncol Date: 2004-12 Impact factor: 5.650